Abstract:Objective To explore the expression and action of tissue factor pathway inhibitor 2 (TFPI-2) in pancreatic carcinoma (PC).
Methods Tissue specimens from 41 pancreatic cancers were used to detect the expression of TFPI-2, Ki67, VEGF and MVD tagged with CD34 by immunohistochemistry.
Results The positive expression of TFPI-2 in stage Ⅰand Ⅱ PC (17/26) was higher than that in stage Ⅲ and Ⅳ (2/15) PC. The positive expression of TFPI-2 in welldifferentiated PC (12/19) was also higher than that in moderate and poorlydifferentiated PC (7/22)(P< 0.05). The cell proliferation index in stage Ⅰ,Ⅱ(24.45±6.19) and welldifferentiated PC (24.42±6.29) was lower than that in stage Ⅲ, Ⅳ (30.84±6.70) and moderate, and poorlydifferentiated PC (28.84±7.12)(P< 0.05). The positive expression of VEGF in stage ⅠandⅡ PC (16/26) was higher than that in stage Ⅲ and Ⅳ (14/15). The positive expression of VEGF in welldifferentiated PC (11/19) was also higher than that in moderate and poorlydifferentiated PC (19/22)(P< 0.05). The value of MVD in stage Ⅰ,Ⅱ(26.92±1.06) and welldifferentiated PC (19.00±2.58) was lower than that in stage of Ⅲ, Ⅳ (28.47±2.23)  and moderate and poorlydifferentiated PC (16.68±1.79), (P< 0.05). The expression of TFPI-2, Ki67 and VEGF was negatively correlated. The MVD was related to the expression of TFPI-2.
Conclusions TFPI-2 can inhibit cell proliferation of PC, and by reducing the expression of VEGF can inhibit the angiogenesis of new vessels in PC, which may play an important part in inhibitory effect on invasion and metastasis of PC.